By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- A new study on Biotechnology is now available. According to news reporting originating in Amherst, Massachusetts, by NewsRx journalists, research stated, "We have examined the role of a novel cytokine, interleukin-27 (IL-27), in mediating interactions between prostate cancer and bone. IL-27 is the most recently characterized member of the family of heterodimeric IL-12-related cytokines and has shown promise in halting tumor growth and mediating tumor regression in several cancer models, including prostate cancer."
The news reporters obtained a quote from the research from the University of Massachusetts, "Prostate cancer is frequently associated with metastases to the bone, where the tumor induces a vicious cycle of communication with osteoblasts and osteoclasts to induce bone lesions, which are a significant cause of pain and skeletal-related events for patients, including a high fracture risk. We describe our findings in the effects of IL-27 gene delivery on prostate cancer cells, osteoblasts, and osteoclasts at different stages of differentiation. We applied the IL-27 gene delivery protocol in vivo utilizing sonoporation (sonodelivery) with the goal of treating and reducing the growth of prostate cancer at a bone metastatic site in vivo. We used a new model of immune-competent prostate adenocarcinoma and characterized the tumor growth reduction, gene expression, and effector cellular profiles. Our results suggest that IL-27 can be effective in reducing tumor growth, can help normalize bone structure, and can promote enhanced accumulation of effector cells in prostate tumors."
According to the news reporters, the research concluded: "These results are promising, because they are relevant to developing a novel IL-27-based strategy that can treat both the tumor and the bone, by using this simple and effective sonodelivery method for treating prostate tumor bone metastases."
For more information on this research see: Interleukin-27 Gene Delivery for Modifying Malignant Interactions Between Prostate Tumor and Bone. Human Gene Therapy, 2013;24(12):970-981. Human Gene Therapy can be contacted at: Mary Ann Liebert, Inc, 140 Huguenot Street, 3RD Fl, New Rochelle, NY 10801, USA. (Mary Ann Liebert, Inc. - www.liebertpub.com; Human Gene Therapy - www.liebertpub.com/overview/human-gene-therapy-and-part-b-methods/19/)
Our news correspondents report that additional information may be obtained by contacting O. Zolochevska, University of Massachusetts, Dept. of Polymer Sci & Engn, Amherst, MA 01003, United States. Additional authors for this research include J. Ellis, S. Parelkar, D. Chan-Seng, T. Emrick, J.N. Wei, I. Patrikeev, M. Motamedi and M.L. Figueiredo (see also Biotechnology).
Keywords for this news article include: Biotechnology, Amherst, Oncology, Cytokines, Interleukins, Massachusetts, United States, Bone Research, Prostate Cancer, Cancer Gene Therapy, Prostatic Neoplasms, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC